Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.
Kim Seong Ho, Song Ji Eun, Hwang Hye Seong, Lee Eun Ji, Kim Tae-Woo, Kim Joon Mo
Latanoprostene bunod significantly lowered IOP in pseudoexfoliation glaucoma (-16.7%) more than POAG (-9.9%) or NVG (-1.4%). This suggests LBN's dual mechanism is highly effective in PXFG, potentially delaying surgery in this challenging patient group.